Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

By Sayar H.   Shen Z.   Lee S.   Royce M.   Rabinowitz I.   Lee F.   Smith H.   Eberhardt S.   Maestas A.   Lu H.   Verschraegen C.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 153-158

Springer Publishing Company

Access to resources Recommend Favorite

Patients with advanced gastric cancer may benefit from treatment with a combination of capecitabine and docetaxel

By  

Inpharma, Vol. 1, Iss. 1442, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

By Lee K.-W.   Park S.   Oh D.-Y.   Park Y.-I.   Khosravan R.   Lin X.   Lee S.-Y.   Roh E.-J.   Valota O.   Lechuga M.   Bang Y.-J.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1547-1558

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

By Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite